1385 related articles for article (PubMed ID: 19135514)
1. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
Bilensoy E; Sarisozen C; Esendağli G; Doğan AL; Aktaş Y; Sen M; Mungan NA
Int J Pharm; 2009 Apr; 371(1-2):170-6. PubMed ID: 19135514
[TBL] [Abstract][Full Text] [Related]
2. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Erdogar N; İskit AB; Eroglu H; Sargon MF; Mungan NA; Bilensoy E
Int J Pharm; 2014 Aug; 471(1-2):1-9. PubMed ID: 24836669
[TBL] [Abstract][Full Text] [Related]
3. Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours.
Erdoğar N; Iskit AB; Mungan NA; Bilensoy E
J Microencapsul; 2012; 29(6):576-82. PubMed ID: 22468630
[TBL] [Abstract][Full Text] [Related]
4. Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.
Men K; Liu W; Li L; Duan X; Wang P; Gou M; Wei X; Gao X; Wang B; Du Y; Huang M; Chen L; Qian Z; Wei Y
Nanoscale; 2012 Oct; 4(20):6425-33. PubMed ID: 22955255
[TBL] [Abstract][Full Text] [Related]
5. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery.
Gou M; Zheng X; Men K; Zhang J; Zheng L; Wang X; Luo F; Zhao Y; Zhao X; Wei Y; Qian Z
J Phys Chem B; 2009 Oct; 113(39):12928-33. PubMed ID: 19736995
[TBL] [Abstract][Full Text] [Related]
6. Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic copolyesters for efficient controlled drug release.
Papadimitriou S; Bikiaris D
J Control Release; 2009 Sep; 138(2):177-84. PubMed ID: 19446585
[TBL] [Abstract][Full Text] [Related]
7. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(epsilon-caprolactone) and chitosan nanoparticles.
Cirpanli Y; Yerlikaya F; Ozturk K; Erdogar N; Launay M; Gegu C; Leturgez T; Bilensoy E; Calis S; Capan Y
Pharmazie; 2010 Dec; 65(12):867-70. PubMed ID: 21284254
[TBL] [Abstract][Full Text] [Related]
9. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro.
Gou M; Zheng L; Peng X; Men K; Zheng X; Zeng S; Guo G; Luo F; Zhao X; Chen L; Wei Y; Qian Z
Int J Pharm; 2009 Jun; 375(1-2):170-6. PubMed ID: 19427143
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle carriers based on copolymers of poly(ε-caprolactone) and hyperbranched polymers for drug delivery.
Wang T; Li M; Gao H; Wu Y
J Colloid Interface Sci; 2011 Jan; 353(1):107-15. PubMed ID: 20947092
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo.
Zhu Z; Li Y; Li X; Li R; Jia Z; Liu B; Guo W; Wu W; Jiang X
J Control Release; 2010 Mar; 142(3):438-46. PubMed ID: 19896997
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
13. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells.
Hu Y; Xie J; Tong YW; Wang CH
J Control Release; 2007 Mar; 118(1):7-17. PubMed ID: 17241684
[TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
15. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
17. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect.
Jia M; Li Y; Yang X; Huang Y; Wu H; Huang Y; Lin J; Li Y; Hou Z; Zhang Q
ACS Appl Mater Interfaces; 2014 Jul; 6(14):11413-23. PubMed ID: 24977925
[TBL] [Abstract][Full Text] [Related]
18. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
[TBL] [Abstract][Full Text] [Related]
19. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
20. A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging.
Ranjan AP; Zeglam K; Mukerjee A; Thamake S; Vishwanatha JK
Nanotechnology; 2011 Jul; 22(29):295104. PubMed ID: 21693801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
